Eagle Pharmaceuticals Inc. has announced its intention to buy Arsia Therapeutics citing its formulation viscosity reduction platform as the driver for the deal.
BASF is poised to start making polyvinylpyrrolidone (PVP) at its facility in Shanghai, China after completing work on a $70m (€62m) manufacturing expansion.
The global excipient certification organization has announced IPEC Association (China) Limited as its fifth member, joining IPEC Europe, IPEC Americas, FECC, and PQG (UK).
Siegfried Holding AG has attributed a surge in API sales to the drug ingredients business it bought from BASF last year, but says that integration costs hurt profits.
German regulators want statin APIs made by Artemis Biotech to be banned after finding deviations good manufacturing practice (GMP) at the firm’s facility in Hyderabad, India.
Xellia Pharmaceuticals has started building a stability and release-testing unit at its API facility in Budapest, Hungary that is designed to support increased output.
The Swiss importer that supplied fake Harvoni to Israel has named the Indian manufacturer from which it bought the drug and is cooperating with an investigation say regulators.
The global active pharmaceuticals ingredients (APIs) market was $119.7 bn in 2014 and is predicted to reach $185.9 bn by 2020, according to a new report.
Novasep has announced it is expanding API synthesis its facility in Boothwyn, Pennsylvania and confirmed that US growth is important after the sale of Pharmachem.
Juniper Pharmaceuticals has made a “significant capital investment” to expand its Xcelodose powder micro-dosing system to feed demand for Phase I study materials.
Pfizer and GlaxoSmithKline have agreed to work together on the development of a new version of the former's continuous processing technology for oral solid dosage (OSD) drugs.
EMD Millipore will offer drugmakers two-years of unlimited access to its suite of raw materials dossiers for 20,000€ as part of its enhanced portfolio offering.
Hospira’s injectables contracting business will operate alongside Pfizer’s CentreSource services unit following the completion of the $17bn takeover deal last week.
Manufacturers of excipients are being sent inappropriate requests for stability data by some regulators and pharma companies, threatening to disrupt the supply chain, IPEC claims.
Ethiopia will start making its own APIs in 2020 according to the Government which says local manufacture will improve access to medicines, curb sale of counterfeits and promote innovation.
China-based CDMO (contract development and manufacturing organization) WuXi PharmaTech has raised about $80m for subsidiary SynTheAll Pharmaceutical Co. (STA) via the private placement of 7.16m common shares of STA stock.
Novasep has signed two partnership agreements for the Japanese markets. The agreements were with Allied Laboratories, a life science and chemical consulting company, and with AR Brown, which will represent Novasep’s CMO services in the Japanese market.
BASF says it remains committed to the pharma industry despite plans to divest its custom synthesis business and around 100 APIs and intermediates to Siegfried Holding.
Fighting drug fakers relies on collaboration according to supply chain security group RX-360, which says drugmakers put rivalries on hold in the war against counterfeiters.
AMRI has confirmed it will close its Holywell, UK facility and let go 62 employees from the site following a consultation with employee representatives.
Makers and distributors of APIs (active pharmaceutical ingredients) will have to track their products throughout the supply chain and meet rules on cold chain transport and outsourcing under revised guidance from the European Commission.
Ongoing demand for large-scale APIs combined with high capacity utilization has driven Cambrex Corporation to allot up to $85m (€70m) for manufacturing expansion in 2015.
